Annual report pursuant to Section 13 and 15(d)

9. Stockholders' Equity (Details Narrative)

v3.19.1
9. Stockholders' Equity (Details Narrative) - USD ($)
 2 Months Ended 12 Months Ended
Mar. 15, 2017
Dec. 31, 2018
Dec. 31, 2017
Proceeds from warrant exercises   $ 1,480,000 $ 0
Warrant-based expense for services   $ 10,206 $ (126,316)
Series B Preferred Stock [Member]      
Stock converted, shares converted   300,000 200,000
Stock converted, shares issued   300,000 200,000
Warrants [Member]      
Warrants exercised   400,000 0
Warrants exercised, stock issued   400,000 0
Pharmsynthez [Member]      
Debt converted, stock issued 100,000    
Debt converted, amount converted $ 500,000    
Serum Institute Warrants [Member]      
Warrants outstanding   539,202 646,249
Warrant-based expense for services   $ 10,000 $ (100,000)
Warrant weighted average exercise price   $ 10.41  
Warrant expiration date range   December 2019 through May 2021  
Financing Agreements [Member]      
Warrants exercised   370,000 0
Warrants exercised, stock issued   370,000  
Proceeds from warrant exercises   $ 1,500,000  
Warrants outstanding   3,152,225 3,522,225
Warrant weighted average exercise price   $ 4.33 $ 4.30
Warrant expiration date range   July 1, 2020 through November 2021  
Warrants granted   0 0